New RNA Drugs Cut Triglycerides by Up to 80% — Rewriting Heart Risk Treatment
A comprehensive review of emerging gene-silencing therapies — ASOs, siRNA, and FGF21 analogs — that slash triglycerides far beyond what statins or fibrates can achieve.
Summary
Hypertriglyceridemia affects roughly 26% of American adults and drives residual cardiovascular risk even when LDL cholesterol is well controlled. This review covers both established treatments — statins (10–30% TG reduction), fibrates (30–50%), and omega-3 fatty acids (20–60%) — and a new wave of RNA-based therapies that target the molecular regulators of triglyceride metabolism. Drugs such as olezarsen and plozasiran (ApoC-III inhibitors), evinacumab and zodasiran (ANGPTL3 inhibitors), and pegozafermin (an FGF21 analog) have achieved triglyceride reductions of up to 80% in clinical trials. These agents also show early signals of reducing acute pancreatitis episodes and improving broader cardiometabolic risk profiles, representing a potential paradigm shift in managing severe or refractory hypertriglyceridemia.
Detailed Summary
Hypertriglyceridemia is classified as moderate (150–499 mg/dL), severe (500–999 mg/dL), or extremely severe (≥1000 mg/dL). NHANES data from 1999–2018 show that about 26% of American adults have moderate elevations, while 0.9% and 0.2% have severe and extremely severe levels, respectively. Even with optimal LDL-lowering, remnant cholesterol from triglyceride-rich lipoproteins conveys significant residual ASCVD risk — a cohort of 93,461 individuals followed for up to 15 years found that remnant cholesterol predicted 73% of incident peripheral artery disease events (95% CI, 32–100%), vastly outpacing LDL cholesterol's contribution of just 8% (95% CI, 0–46%). This biochemical distinction underlies the clinical urgency for more powerful triglyceride-lowering strategies.
The molecular architecture of triglyceride metabolism is now well enough understood to permit highly targeted intervention. Lipoprotein lipase (LPL) is the central enzyme hydrolyzing triglycerides in chylomicrons and VLDL; its activity is activated by ApoC-II and ApoA5, and suppressed by ApoC-III and the angiopoietin-like proteins ANGPTL3, ANGPTL4, and ANGPTL8. ApoC-III also blocks ApoE-mediated hepatic clearance of remnant particles independent of LPL. Inhibiting ApoC-III or ANGPTL3 therefore addresses two complementary rate-limiting steps simultaneously, which explains the outsized efficacy of agents hitting these targets.
Among established therapies, statins reduce triglycerides by 10–30% dose-dependently, fibrates by 30–50% via PPAR-α activation, and prescription omega-3 fatty acids (EPA/DHA at 3–4 g/day) by 20–60%, with greater reductions at higher baseline levels. Niacin achieves 20–50% reductions but is rarely recommended today due to poor tolerability, flushing, hepatotoxicity risk, and lack of proven cardiovascular outcome benefit. These agents fail many patients with severe or genetically driven hypertriglyceridemia.
The emerging pipeline targets three nodes: ApoC-III, ANGPTL3, and FGF21. Volanesorsen, an antisense oligonucleotide (ASO) against ApoC-III, demonstrated ~77% triglyceride reduction in familial chylomicronemia syndrome (FCS) and is approved in Europe. Olezarsen, a next-generation ApoC-III ASO with a GalNAc conjugate enabling hepatic targeting and subcutaneous monthly dosing, showed ~60–70% triglyceride reductions in phase 2/3 trials with a more favorable safety profile. Plozasiran, a GalNAc-siRNA targeting ApoC-III, achieved reductions exceeding 70–80% in phase 2 trials and is progressing through phase 3 evaluation. On the ANGPTL3 side, evinacumab (a monoclonal antibody) and zodasiran (a GalNAc-siRNA) reduce triglycerides substantially and also lower LDL cholesterol, making them attractive for patients with combined dyslipidemia. Pegozafermin, a PEGylated FGF21 analog, addresses hypertriglyceridemia partly via improved insulin sensitivity and hepatic lipid metabolism, with additional benefits on NASH/MAFLD endpoints.
Clinically, preliminary data suggest these agents may reduce acute pancreatitis incidence in FCS and severe hypertriglyceridemia, but dedicated outcomes trials remain pending. Individualized treatment selection — based on etiology (primary genetic vs. secondary), baseline TG severity, co-morbidities, and route of administration — will be essential. Monthly or quarterly subcutaneous dosing of the GalNAc-conjugated agents may substantially improve adherence compared to daily oral therapies. Physicians should also continue to address secondary causes such as poorly controlled diabetes, hypothyroidism, alcohol use, and offending medications before or alongside initiating these novel therapies.
Key Findings
- Remnant cholesterol predicted 73% of incident peripheral artery disease events vs. only 8% for LDL cholesterol in a 93,461-person cohort followed up to 15 years
- Plozasiran (ApoC-III siRNA) and volanesorsen (ApoC-III ASO) achieved triglyceride reductions of up to 77–80% in clinical trials of FCS and severe hypertriglyceridemia
- Olezarsen, a GalNAc-conjugated ApoC-III ASO, demonstrated 60–70% TG reductions with improved tolerability and monthly subcutaneous dosing vs. earlier ASO agents
- Established fibrates reduce triglycerides 30–50%, omega-3 fatty acids (3–4 g/day) 20–60%, and statins only 10–30% — all insufficient for severe or refractory cases
- ANGPTL3 inhibitors (evinacumab monoclonal antibody; zodasiran siRNA) reduce both triglycerides and LDL cholesterol, offering dual cardiometabolic benefit
- Pegozafermin (FGF21 analog) lowers triglycerides and shows concurrent improvements in liver fat and insulin sensitivity, relevant for patients with MASLD
- 5–10% body weight reduction alone can lower triglycerides by 10–30%, and up to 70% in some cases, underscoring lifestyle as foundational even in the era of RNA drugs
Methodology
This is a narrative review based on literature searches of PubMed, Scopus, and ClinicalTrials.gov using terms including 'hypertriglyceridemia', 'ApoC-III inhibitors', 'ANGPTL3 inhibitors', 'siRNA', 'antisense oligonucleotides', and 'FGF21 analogs', covering publications through 2025. Priority was given to clinical trials, meta-analyses, and high-impact recent publications. Non-English articles and studies not directly addressing triglyceride metabolism or pharmacological management were excluded. As a narrative rather than systematic review, formal quality assessment and PRISMA-style evidence grading were not applied.
Study Limitations
As a narrative review, this study is subject to selection bias in the literature chosen and does not apply formal systematic review methodology or GRADE evidence quality assessment. Many of the emerging therapies discussed — particularly plozasiran and zodasiran — are still in phase 2 or 3 trials, meaning long-term cardiovascular outcomes data are not yet available. The single authorship and funding from a university deanship represent low conflict-of-interest risk, but independent confirmation of the evidence synthesis would strengthen conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: